Department of Genetics, Center for Molecular Medicine, University Medical Center Utrecht, Utrecht, the Netherlands.
The Epilepsy Institutes of the Netherlands Foundation (SEIN).
Epilepsia. 2018 Mar;59(3):690-703. doi: 10.1111/epi.14021. Epub 2018 Feb 20.
Phenotypes caused by de novo SCN1A pathogenic variants are very variable, ranging from severely affected patients with Dravet syndrome to much milder genetic epilepsy febrile seizures plus cases. The most important determinant of disease severity is the type of variant, with variants that cause a complete loss of function of the SCN1A protein (α-subunit of the neuronal sodium channel Nav1.1) being detected almost exclusively in Dravet syndrome patients. However, even within Dravet syndrome disease severity ranges greatly, and consequently other disease modifiers must exist. A better prediction of disease severity is very much needed in daily practice to improve counseling, stressing the importance of identifying modifying factors in this patient group. We evaluated 128 participants with de novo, pathogenic SCN1A variants to investigate whether mosaicism, caused by postzygotic mutation, is a major modifier in SCN1A-related epilepsy.
Mosaicism was investigated by reanalysis of the pathogenic SCN1A variants using single molecule molecular inversion probes and next generation sequencing with high coverage. Allelic ratios of pathogenic variants were used to determine whether mosaicism was likely. Selected mosaic variants were confirmed by droplet digital polymerase chain reaction and sequencing of different tissues. Developmental outcome was classified based on available data on intelligence quotient and school functioning/education.
Mosaicism was present for 7.5% of de novo pathogenic SCN1A variants in symptomatic patients. Mosaic participants were less severely affected than nonmosaic participants if only participants with truncating variants are considered (distribution of developmental outcome scores, Mann-Whitney U, P = .023).
Postzygotic mutation is a common phenomenon in SCN1A-related epilepsies. Participants with mosaicism have on average milder phenotypes, suggesting that mosaicism can be a major modifier of SCN1A-related diseases. Detection of mosaicism has important implications for genetic counseling and can be achieved by deep sequencing of unique reads.
由从头发生的 SCN1A 致病性变异引起的表型非常多样化,从患有 Dravet 综合征的严重影响患者到更温和的遗传性癫痫热性惊厥附加症病例。疾病严重程度的最重要决定因素是变异类型,导致 SCN1A 蛋白(神经元钠离子通道 Nav1.1 的 α 亚基)完全丧失功能的变异几乎仅在 Dravet 综合征患者中检测到。然而,即使在 Dravet 综合征患者中,疾病严重程度也有很大差异,因此一定存在其他疾病修饰因子。在日常实践中,非常需要更准确地预测疾病严重程度,以改善咨询,强调在这一患者群体中识别修饰因子的重要性。我们评估了 128 名患有从头发生的致病性 SCN1A 变异的参与者,以研究是否合子后突变引起的嵌合现象是 SCN1A 相关癫痫的主要修饰因子。
通过使用单分子分子反转探针和高覆盖率的下一代测序重新分析致病性 SCN1A 变异来研究嵌合体现象。致病性变异的等位基因比例用于确定是否存在嵌合体现象。选择的嵌合变体通过液滴数字聚合酶链反应和不同组织的测序进行确认。根据智商和学校功能/教育方面的可用数据对发育结果进行分类。
在有症状的患者中,7.5%的从头发生的致病性 SCN1A 变异存在嵌合体现象。如果仅考虑截断变异的参与者,嵌合参与者的病情比非嵌合参与者轻(发育结果评分的分布,Mann-Whitney U,P=0.023)。
合子后突变是 SCN1A 相关癫痫的常见现象。嵌合参与者的表型平均较轻,表明嵌合体现象可以是 SCN1A 相关疾病的主要修饰因子。通过独特读取的深度测序可以检测到嵌合体现象,这对遗传咨询具有重要意义。